← Browse by Condition
Medical Condition
prostate cancer metastatic
Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 3
Cancer clinical trials represent the largest single category of recruiting studies worldwide, encompassing everything from early-phase safety studies of novel oncology drugs to large Phase 3 comparisons against current standard-of-care chemotherapy regimens. The field has accelerated dramatically with the rise of immunotherapy, targeted therapies, and CAR-T cell treatments that have transformed outcomes for previously untreatable malignancies.
Trials include checkpoint inhibitors (PD-1/PD-L1 agents), KRAS inhibitors, ADC (antibody-drug conjugates), combination chemotherapy regimens, radiation protocols, and surgical technique comparisons. Many trials stratify by biomarker status (PD-L1 expression, TMB, MSI-H) to identify patients most likely to benefit.
The NCI, pharmaceutical sponsors, and academic cancer centers collectively fund thousands of oncology trials annually across every cancer type.
Frequently Asked Questions — prostate cancer metastatic Clinical Trials
How many clinical trials are currently recruiting for prostate cancer metastatic?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for prostate cancer metastatic, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for prostate cancer metastatic?
prostate cancer metastatic research spans Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a prostate cancer metastatic clinical trial?
Eligibility criteria for prostate cancer metastatic trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2 2
Phase 3 1
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06141993
Recruiting
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Enrollment
120 pts
Location
United States
Sponsor
Duke University
NCT06972628 Phase 2
Recruiting
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Enrollment
30 pts
Location
United States
Sponsor
Ebrahim S Delpassand
NCT05242744
Recruiting
FTT PET/CT in Metastatic Prostate Cancer
Enrollment
30 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
NCT05457699 Phase 2
Recruiting
Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
Enrollment
80 pts
Location
Canada
Sponsor
Centre hospitalier de l'Univer...
NCT05000827
Recruiting
Dutch National Randomized Study: PSMA-PET/CT As a Triage Tool for Pelvic Lymph Node Dissection in Prostatectomy Patients
Enrollment
706 pts
Location
Netherlands
Sponsor
Canisius-Wilhelmina Hospital
NCT04916613 Phase 3
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
Enrollment
300 pts
Location
Belgium, France, Ger...
Sponsor
UNICANCER
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology